Business
Thermo Fisher Scientific Launches CorEvitas Obesity Registry to Advance Real-World Evidence in Treatment Outcomes
WALTHAM, Mass., January 06, 2026--Thermo Fisher Scientific launches CorEvitas Obesity Registry to advance real-world evidence in treatment outcomes.
About this update from Thermo Fisher Scientific Inc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1590,"height":341,"url":"https://media.zenfs.com/en/business-wire.com/f31472b1115208e83089ae5b7d063cdb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mu2gNbkFJLotuCkC884vvw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwNjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f31472b1115208e83089ae5b7d063cdb","width":960,"height":206},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/usjIQHTXXBpSOg_3lDFVwQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MTQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/f31472b1115208e83089ae5b7d063cdb","width":1200,"height":257}},"lazy":false},{"type":"text","content":"WALTHAM, Mass., January 06, 2026--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the enrollment of the first patient in the new PPD™ CorEvitas™ Obesity Registry. This prospective, observational registry will generate real-world evidence on the long-term effectiveness, safety and patient experience associated with obesity management therapies, including anti-obesity medications. By collecting insights directly from both clinicians and patients, the registry will provide critical insights into treatment patterns, adherence, satisfaction and clinical outcomes, including anthropomorphic measures, across diverse care settings.","length":683,"tagName":"p"},{"type":"text","content":"Obesity is a chronic, complex disease influenced by genetic, environmental and psychosocial factors and is linked to significant comorbidities such as type 2 diabetes, heart disease and certain cancers. It also impacts quality of life, mobility and mental health. In the United States, more than 100 million adults live with obesity, while more than 22 million adults experience severe obesity1. Globally, the economic impact of overweight and obesity is projected to reach $3 trillion annually by 2030, rising to over $18 trillion by 20602.","length":541,"tagName":"p"},{"type":"text","content":""The CorEvitas Obesity Registry represents a major step forward in understanding the use and outcomes associated with obesity treatments in everyday clinical practice," said Leslie Harrold, M.D., vice president and global head of real-world science and strategy for PPD CorEvitas ...